The use of PVP as a polymeric carrier to improve the plasma half-life of drugs

To achieve an optimum drug delivery such as targeting or controlled release utilizing bioconjugation with polymeric modifier, the conjugate between drugs and polymeric modifiers must be designed to show desirable pharmacokinetic characteristics in vivo. In this study, we assessed the biopharmaceutic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomaterials 2004-07, Vol.25 (16), p.3259-3266
Hauptverfasser:	Kaneda, Yoshihisa, Tsutsumi, Yasuo, Yoshioka, Yasuo, Kamada, Haruhiko, Yamamoto, Yoko, Kodaira, Hiroshi, Tsunoda, Shin-ichi, Okamoto, Takayuki, Mukai, Yohei, Shibata, Hiroko, Nakagawa, Shinsaku, Mayumi, Tadanori
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Bioconjugation Cell Line, Tumor Drug Carriers - administration & dosage Drug Carriers - chemistry Drug Carriers - pharmacokinetics Drug Evaluation - methods Drug Stability Female Fibrosarcoma - metabolism Half-Life Male Metabolic Clearance Rate Mice Mice, Inbred BALB C Organ Specificity Polyethylene glycol (PEG) Polymeric modifier Polymers - administration & dosage Polymers - chemistry Polymers - pharmacokinetics Polyvinylpyrrolidone (PVP) Povidone - administration & dosage Povidone - chemistry Povidone - pharmacokinetics Tissue Distribution Tumor necrosis factor-alpha (TNF- α) Tumor Necrosis Factor-alpha - administration & dosage Tumor Necrosis Factor-alpha - analysis Tumor Necrosis Factor-alpha - chemistry Tumor Necrosis Factor-alpha - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!